José Ángel Alcalá Partera

Dr. José Ángel Alcalá Partera

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2021 in European Psychiatry
Verified
Journal Article
Open access
PDF file
MJMaría Jose Jaén-Moreno
María Jose Jaén-Moreno
NFN. Feu
N. Feu
GPG. I. del Pozo
G. I. del Pozo
CGC. Gómez
C. Gómez
LCL. Carrión
L. Carrión
FSF. Sarramea
F. Sarramea
This study has two main objectives: to describe the prevalence of undetected chronic obstructive pulmonary disease (COPD) in a clinical sample of smokers with severe mental illness (SMI), and to assess the value of the Tobacco Intensive Motivational Estimated Risk tool, which informs smokers of their respiratory risk and uses brief text messages to reinforce intervention. A multicenter, randomized, open-label, and active-controlled clinical trial, with a 12-month follow-up. Outpatients with schizophrenia (SZ) and bipolar disorder were randomized either to the experimental group—studied by spirometry and informed of their calculated lung age and degree of obstruction (if any)—or to the active control group, who followed the 5 A’s intervention. The study sample consisted of 160 patients (71.9% SZ), 78.1% of whom completed the 12-month follow-up. Of the patients who completed the spirometry test, 23.9% showed evidence of COPD (77.8% in moderate or severe stages). TIMER was associated with a significant reduction in tobacco use at week 12 and in the long term, 21.9% of patients reduced consumption and 14.6% at least halved it. At week 48, six patients (7.3%) allocated to the experimental group achieved the seven-day smoking abstinence confirmed by CO (primary outcome in terms of efficacy), compared to three (3.8%) in the control group. In this clinical pilot trial, one in four outpatients with an SMI who smoked had undiagnosed COPD. An intensive intervention tool favors the early detection of COPD and maintains its efficacy to quit smoking, compared with the standard 5 A’s intervention.

JPJosé Ángel Alcalá Partera
José Ángel Alcalá Partera
AFAndrés Fontalba-Navas
Andrés Fontalba-Navas
Miguel CompanyMiguel Company
Miguel Company
SRSamuel Leopoldo Romero-Guillena
Samuel Leopoldo Romero-Guillena
TGTeófilo Gutiérrez-Higueras
Teófilo Gutiérrez-Higueras
LGLuis Gutiérrez-Rojas
Luis Gutiérrez-Rojas
One of the big challenges in treating individuals with bipolar disorder (BD) is nonadherence to medication. This is the principal factor associated with a worse prognosis or outcome of the disease. This study aimed to explore and analyze the individual perceptions that people with BD have about the positive and negative aspects when taking medication. A descriptive and interpretative study was carried out using the qualitative research paradigm with the use of the analytical technique of discourse analysis, extracting the data through the completion of focus groups. Participants’ speech was digitally audio-recorded in digital format. In order to complete the codification of the participants’ speech content, we relied on the qualitative data analysis (using the QRS NVivo 10 computer software). Thirty-six participants diagnosed with bipolar disorder took part in our study. In the participants’ speech concerning the main barriers to pharmacological treatment, three key topics were identified. Perceived facilitators were summarized in four factors. The main facilitators regarding the use of pharmacological treatment in individuals with BD were the ones related with the perceived need for treatment in the acute phase, the recognition of the illness, the shared clinical decision, and the causal biological attribution in the chronic phase. In terms of perceived barriers, social control was identified in both phases, adverse effects in the acute phase, and the absence of effective treatment in the chronic state.

14 January 2019 in Trials
Verified
Journal Article
Open access
PDF file
MJMaría Jose Jaén-Moreno
María Jose Jaén-Moreno
NFNuria Feu
Nuria Feu
JRJusta Redondo-Écija
Justa Redondo-Écija
FMFrancisco Javier Montiel
Francisco Javier Montiel
CGCristina Gómez
Cristina Gómez
FSFernando Sarramea
Fernando Sarramea
There is an increased risk of premature death in people with severe mental illness (SMI). Respiratory disorders and cardiovascular disease are leading causes of increased mortality rates in these patients, and tobacco consumption remains the most preventable risk factor involved. Developing new tools to motivate patients towards cessation of smoking is a high priority. Information on the motivational value of giving the lung age and prevention opportunities is unknown in this high-risk population. This article describes in detail a protocol developed to evaluate an intensive motivational tool, based on the individual risks of pulmonary damage and prevention opportunities. It is designed as a randomized, 12-month, follow-up, multicenter study. A minimum of 204 smokers will be included, aged 40 years and older, all of whom are patients diagnosed with either schizophrenia or bipolar disorder (BD). Chronic obstructive pulmonary disease (COPD) will be evaluated using spirometry, and the diagnosis will then be validated by a pneumologist and the lung age estimated. Based on this value, a motivational message about prevention will be issued for the intervention group, which will be reinforced by individualized text messages over a period of 3 months. The efficacy of the method and the pulmonary damage variables will be evaluated: smoking cessation at the end of follow-up will be confirmed by cooximetry, and the COPD diagnosis and the severity of the staging for disease will be assessed. In the context of community care, screening and early detection of lung damage could potentially be used, together with mobile technology, in order to produce a prevention message, which may provide patients with SMI with a better chance of quitting smoking. ClinicalTrials.gov, ID: NCT03583203 . Registered on 11 July 2018. Trial status: recruitment.

1 July 2025 in Frontiers in Psychiatry
Verified
Journal Article
Open access
PDF file
JPJosé Ángel Alcalá Partera
José Ángel Alcalá Partera
VDVerónica Olmo Dorado
Verónica Olmo Dorado
GHGuadalupe del Pilar Arilla Herrera
Guadalupe del Pilar Arilla Herrera
SCSilvia López Chamón
Silvia López Chamón
VMVicente Gasull Molinera
Vicente Gasull Molinera
The management of patients with major depressive disorder (MDD) in primary care (PC) represents a significant challenge and a great opportunity for early and effective intervention. Primary care physicians, as first-line physicians, play a key role in the identification, diagnosis and initial treatment of depression, often being the first and sometimes the only point of contact for these patients with the healthcare system. In this context, the search for effective and well-tolerated therapeutic strategies is constant, and vortioxetine represents a good pharmacological option within the therapeutic armamentarium available to the PC physician. This article explores best practices in the management of MDD from the PC perspective, addressing the specific challenges faced by these professionals and examining the potential role of vortioxetine in the treatment of different patient profiles.

3 December 2025 in European Psychiatry
Verified
Journal Article
Open access
PDF file
MJMaría Jose Jaén-Moreno
María Jose Jaén-Moreno
DLDavid Laguna-Muñoz
David Laguna-Muñoz
GPGloria Isabel del Pozo
Gloria Isabel del Pozo
CCCristina Camacho-Rodríguez
Cristina Camacho-Rodríguez
IGIpek Guler
Ipek Guler
FSFernando Sarramea
Fernando Sarramea
Background: The population with a serious mental illness (SMI) shows a high risk of premature mortality. Overexposed to multiple health risks throughout life, their main threat is physical illness, which starts earlier and is not diagnosed in time. Developing preventive actions is a public health priority. Methods: This longitudinal prospective study evaluated the predictive value of lung function on all-cause mortality in patients with schizophrenia (SCHIZ) or bipolar disorder. Patients aged 40–70 years, active smokers, and without preexisting respiratory disease underwent spirometry following American Thoracic Society/European Respiratory Society 2021 standards. Mortality data were collected through December 2022. Cox proportional hazards models and Kaplan–Meier survival curves analyzed the association between lung function, specifically forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), and mortality, adjusting for relevant confounders (age, gender, abdominal circumference, and comorbidities). Results: Of 107 participants (mean age 49.3 years, 63.3% male) with SMI (72% SCHIZ) and active smokers, 8 (7.5%) died during the 6-year follow-up (5 cardiovascular and 3 cancer). Mean z -scores were −1.41 (SD = 1.22) for FEV1 and −0.99 (SD = 1.16) for FVC. Lower FEV1 and FVC z -scores were significantly associated with increased mortality risk ( p = 0.002 and p = 0.009, respectively). Kaplan–Meier analysis confirmed this association for FEV1 ( p = 0.039) and FVC ( p = 0.007) but not for gender, comorbidities (hypertension, diabetes, and dyslipidemia), or FEV1/FVC. A multivariate Cox regression model, adjusting for age and abdominal circumference, confirmed the independent predictive value of lower FEV1 z -score for mortality (hazard regression = 0.473, 95% confidence interval: 0.220–0.979, p = 0.044). Conclusions: Poorer lung function, especially lower FEV1, was independently associated with all-cause mortality in SMI. Spirometry, an easily implementable technique, could help to detect at-risk individuals and favor prevention initiatives.

1 September 2026 in Journal of Psychiatric Practice
Verified
Journal Article
Open access
JMJose Martinez-Raga
Jose Martinez-Raga
BSBegoña Soler-López
Begoña Soler-López
JPJosé Ángel Alcalá Partera
José Ángel Alcalá Partera
DGDUME Study Group
DUME Study Group
Background and Objectives: Duloxetine is a serotonin and norepinephrine reuptake inhibitor antidepressant drug. The goal of this project was to analyze the characteristics of patients with major depressive disorder (MDD) treated with duloxetine in the high-dose range (90 to 120 mg). Methods: A retrospective, multicenter study was designed to analyze 20 indicators on the clinical use of duloxetine (90 to 120 mg) in adults with MDD who were referred to the psychiatric clinic. Results: A total of 175 psychiatrists participated in the study and collected information on 1050 patients with a mean age of 51.3 years (62.9% women). A total of 55.4% had comorbid psychiatric conditions, with dysthymia (17.2%), generalized anxiety disorder (15%), and personality disorders (13.1%) being the most common. A total of 84.7% had nonpsychiatric conditions, including chronic pain (28.8%), fibromyalgia (22.4%), sleep disorders (20.5%), arterial hypertension (17.8%), dyslipidemia (16.3%), neuropathic pain (11.4%), and cognitive impairment (5.8%). In all, 45.3% of the sample were found to be markedly to extremely ill. A total of 84.3% had received 1 to more than 4 prior lines of therapy. The most common reason for prescribing duloxetine in the high-dose range was a lack of efficacy of previous treatment (41%) or because the patient showed only a partial response to lower doses of duloxetine (30.7%). Conclusion: A greater than expected proportion of patients with advanced, marked, or severe disease, psychiatric comorbidity, sleep disorders, neuropathic pain, and cognitive impairment was observed among the subjects with MDD treated with high-dose duloxetine.